The D3 receptor (D3R) has emerged as a promising pharmacotherapeutic target for the treatment of several diseases including schizophrenia, Parkinson's disease, and substance use disorders. However, studies investigating the modulatory impact of D3R antagonism on dopamine neurotransmission or the effects drugs of abuse have produced mixed results, in part because D3R-targeted compounds often also interact with D2 receptors (D2R). The purpose of this study was to compare the consequences of selective D2R or D3R antagonism on the behavioral effects of cocaine in mice, and to identify the neurobiological mechanisms underlying their modulatory effects. Methods: We characterized the effects of selective D2R or D3R antagonism in mice on 1) basal and cocaine-induced locomotor activity, 2) presynaptic dopamine release and clearance in the nucleus accumbens using ex vivo fast scan cyclic voltammetry, and 3) dopamine-mediated signaling in D1-expressing and D2-expressing medium spiny neurons using ex vivo electrophysiology. Results: Pretreatment with the selective D2R antagonist L-741,626 attenuated, while pretreatment with the selective D3R antagonist PG01037 enhanced, the locomotor-activating effects of acute and repeated cocaine administration. While both antagonists potentiated cocaine-induced increases in presynaptic DA release, D3R blockade uniquely facilitated DAmediated excitation of D1-expressing medium spiny neurons in the nucleus accumbens. Conclusions: Selective D3R antagonism potentiates the behavioral-stimulant effects of cocaine in mice, an effect that is in direct opposition to that produced by selective D2R antagonism or nonselective D2-like receptor antagonists, likely by facilitating D1-mediated excitation in the nucleus accumbens. These findings provide important insights into the neuropharmacological actions of D3R antagonists on mesolimbic dopamine neurotransmission.
by examining each antagonist's effect on stimulated presynaptic DA release and DA clearance in the NAc via ex vivo fast-scan cyclic voltammetry (FSCV), as well as their impact on the activity of NAc D1-MSNs and D2-MSNs using ex vivo whole cell electrophysiology.
Methods and Materials

Animals
All procedures were performed in strict accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees of Emory University or University of Texas at San Antonio. Additional details are provided in the Supplement.
Effects of Selective D3R or D2R Antagonism on Locomotor Behavior
The effects of systemic pretreatment with PG01037 or L-741,626 on basal and cocaine-induced locomotor activity were assessed using methods adapted from those previously described (61, 62) . Detailed methodological descriptions for drug treatments and locomotor measurements are provided in the Supplement.
Effects of Selective D3R or D2R Antagonism on Presynaptic DA Release in NAc
Ex vivo slice FSCV was performed as described previously (63, 64) to determine the impact of PG01037 or L-741,626 on stimulated DA release and clearance, and cocaine-induced modulations of these measures, in the NAc. Detailed methods are provided in the Supplement.
Effects of Selective D3R or D2R Antagonism on Postsynaptic D1-MSN or D2-MSN Activity in NAc
NAc D1-MSN and D2-MSN activity was assessed using ex vivo electrophysiology in slices derived from Drd1a-tdTomato and Drd2-EGFP mice. A detailed description of the recording methods is provided in the Supplement.
Statistics
Data were analyzed using either paired t-test, one-way repeated measures (RM) analysis of variance (ANOVA), or two-way ANOVA (RM on one or both factors) with post hoc Dunnett's or Holm-Sidak's tests as specified. See the Supplement for additional details. GraphPad Prism v. 7 .04 (GraphPad Software, La Jolla, CA) was used to perform all statistical analyses. Significance was set at p < 0.05 for all tests.
Results
Pretreatment with Selective D2R or D3R Antagonists Produces Opposite Effects on Cocaine-Induced Locomotion.
Neither of the active doses of L-741,626 (3.0 or 10.0 mg/kg) significantly affected basal locomotor activity, assessed over the first 30 min following drug administration ( Figure 1A) . By contrast, cocaine-induced increases in locomotor activity were robustly attenuated by L-741,626 pretreatment ( Figure 1B ). Analyses revealed that 10.0 mg/kg L-741-626 significantly reduced the locomotor-activating effects of each cocaine dose, shifting the cocaine dose-response function rightward and downward ( Figure 1B) . The effects of L-741,626 were evident immediately after cocaine administration and persisted throughout the observation period (Supplemental Figure S1A-C).
Chronic exposure to cocaine produces neurobiological adaptations that cause sensitized behavioral and neurochemical responses to subsequent cocaine challenges (65) (66) (67) . We wondered whether blockade of D2Rs would modulate the induction of locomotor sensitization following repeated exposure to cocaine. Mice treated with the daily combination of vehicle + 15.0 mg/kg cocaine exhibited a robust sensitization of cocaine-induced locomotion, but the development of sensitization was abolished by daily pretreatment with 10.0 mg/kg L-741,626 prior to 15.0 mg/kg cocaine ( Figure 1C ). Notably, administration of 10.0 mg/kg L-741,626 alone (i.e. prior to saline) did not produce significant changes in locomotor activity ( Figure 1C ).
We next assessed the effects of pretreatment with the selective D3R antagonist PG01037 on acute cocaine-induced increases in locomotion. Neither of the active doses of PG01037 (1.0 or 10.0 mg/kg) significantly affected basal locomotor activity ( Figure 1D ). In direct opposition to the effects of L-741,626, cocaine-induced increases in locomotor activity were enhanced following pretreatment with PG01037 ( Figure 1E ). Analyses showed that pretreatment with 10.0 mg/kg PG01037 produced a leftward and upward shift of the cocaine dose-response function ( Figure 1E ). The potentiation of cocaine-induced locomotion by PG01037 occurred immediately upon cocaine administration and was not attributable to a prolongation of cocaine's time course of action (Supplemental Figure S2A -C). Based on these results, we hypothesized that PG01037 may similarly potentiate cocaine-induced sensitization. We optimized our sensitization protocol for the detection of enhanced sensitization by testing the effects of PG01037 in conjunction with a low dose of cocaine (5.0 mg/kg) that does not induce behavioral sensitization alone. Mice treated with the daily combination of vehicle + saline, vehicle + 5.0 mg/kg cocaine, or 10.0 mg/kg PG01037 + saline failed to exhibit sensitization. By contrast, sensitized locomotor responses developed in mice pretreated daily with 10.0 mg/kg PG01037 prior to 5.0 mg/kg cocaine ( Figure 1F ).
Previous work has shown that intra-NAc administration of nonselective D2-like antagonists attenuates cocaine-induced locomotor activity (68, 69) . However, studies investigating the specific role of the D3R subtype in modulating cocaine-induced locomotion have produced mixed results (39, 45, (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . We therefore investigated whether intra-NAc infusion of PG01037 would recapitulate the effects of systemic D3R blockade described above. In a separate cohort of mice, we delivered bilateral intra-NAc infusions of PG01037 (3 µg/side) or vehicle (aCSF) via guide cannula followed immediately by i.p. administration of 10.0 mg/kg cocaine. Intra-NAc delivery of PG01037 enhanced cocaine-induced locomotor activity (Supplemental Figure S3A-B ), suggesting that the NAc is a critical site in which D3R antagonists act to potentiate the locomotor-activating effects of cocaine.
Selective Blockade of D2R or D3R Facilitates Cocaine-Induced Increases in NAc DA
Release.
The results described above demonstrate that D2R antagonism attenuates, while D3R antagonism enhances, the behavioral-stimulant effects of cocaine. Moreover, previous findings (68, 69) and our present work (Supplemental Figure S3 ) indicated that the NAc is a key neuroanatomical substrate for these effects. However, the neuropharmacological mechanisms underlying these disparate outcomes remained unresolved. Within the NAc, D2Rs and D3Rs function both as presynaptic autoreceptors on DAergic terminals and as postsynaptic heteroreceptors on MSNs (8, 9) , and are thus positioned to modulate presynaptic DA release and postsynaptic DA receptor-mediated changes in neuronal activity, respectively. We therefore sought to address whether D2R or D3R antagonism similarly or distinctly impact each of these measures.
We first quantified electrically-evoked presynaptic DA release in the NAc in the presence of D2R or D3R antagonists alone and in combination with cocaine using ex vivo slice FSCV. Figures 2A and 2B show representative color plots and current traces for DA detection with increasing concentrations of L-741,626. Application of L-741,626 alone failed to alter peak stimulated DA release ( Figure 2C ) or the rate of DA clearance ( Figure 2D ). Figures 2E and 2F show representative color plots and current traces for DA detection following combined application of cocaine (1 µ M) and increasing concentrations of L-741,626. Cocaine enhanced stimulated DA release compared to baseline as reported previously (70, 71) , and application of 100 pM L-741,626 potentiated the cocaine-induced increase in DA release ( Figure 2G ). Application of the highest concentration of L-741,626 (1 nM) trended towards producing this effect as well. Statistical analysis narrowly failed to detect a significant main effect of condition on DA clearance, although cocaine produced an expected increase in tau that was seemingly unaffected by co-application of L-741,626 ( Figure 2H ).
Figures 3A and 3B show representative color plots and current traces for DA detection with increasing concentrations of PG01037. Application of PG01037 alone did not alter peak stimulated DA release ( Figure 3C ) or DA clearance ( Figure 3D ). Figures 3E and 3F show representative color plots and current traces for DA detection following combined application of cocaine (1 µM) and increasing concentrations of PG01037. Cocaine increased peak stimulated DA release and this effect was further enhanced following application of 100 pM or 1 nM PG01037 ( Figure 3G ). Cocaine also produced an expected increase in tau value, but in contrast to L-741,626, co-application of PG01037 potentiated this effect ( Figure 3H ).
Selective Blockade of D2R or D3R Produces Differential Effects on Neuronal Firing in NAc D1-MSNs, but not D2-MSNs.
We next examined potential postsynaptic differences by performing ex vivo whole cell electrophysiology to examine changes in activity of NAc D1-MSNs and D2-MSNs following combined application of DA and selective D2R or D3R antagonists. Shown in Figure 4A -D are the effects of L-741,626 on DA-mediated changes in D1-MSN activity. DA application alone significantly increased spike frequency as compared to baseline, but co-administration of L-741,626 did not modulate this effect of DA ( Figure 4B ). Neither the application of DA alone nor the co-application of DA + L-741,626 affected F-I slope ( Figure 4C ), and the DA-mediated reduction of rheobase in D1-MSNs was similarly unaffected following co-administration with L-741,626 ( Figure 4D ). By contrast, application of PG01037 modulated several DA-mediated changes in D1-MSN activity ( Figure 4E -H). Combined administration of DA + PG01037 increased spike frequency as compared to both baseline and DA alone conditions, an observation that was accompanied by an increase in the slope of the F-I curve ( Figure 4G ). Furthermore, application of DA significantly reduced rheobase as compared to baseline, and PG01037 potentiated this effect ( Figure 4H ).
The effects of L-741,626 on D2-MSN spike frequency are shown in Figure 5A -D. Application of either DA alone or DA + L-741,626 significantly reduced spike frequency as compared to baseline, but the effects of combined administration of DA + L-741,626 did not significantly differ from the DA alone condition ( Figure 5B ). None of the treatments significantly affected the slope of the F-I curve as compared to baseline ( Figure 5C ). In agreement with results on firing rate, rheobase values were significantly increased in the DA alone and DA + L-741,626 conditions as compared to baseline, but did not significantly differ from each other ( Figure 5D ). We next tested the impact of PG01037 application on D2-MSN spike frequency ( Figure 5E -H). As compared to baseline, the application of either DA alone or DA + PG01037 reduced spike frequency ( Figure 5F ), but the DA alone and DA + PG01037 conditions did not significantly differ from each other. F-I slope was unaffected by any treatment compared to baseline ( Figure 5G ). Finally, application of DA alone or DA + PG01037 significantly increased rheobase values compared to baseline, but not differ from each other ( Figure 5H ).
The results obtained from recordings in D2-MSNs indicated that DA reduced the excitability of these neurons, but selective blockade of either D2Rs or D3Rs alone was incapable of reversing this effect. Because D2-MSNs co-express D2Rs and D3Rs, we speculated that singular pharmacological blockade of either receptor alone fails to alleviate DA-mediated inhibition because DA binding at the spared receptor subtype is sufficient to exert efficacious inhibitory action on the cell. To test this hypothesis, we first assessed DA-mediated inhibition of spike frequency in D2-MSNs following administration of the nonselective D2R/D3R antagonist sulpiride. DA alone again produced an expected reduction in spike frequency, but the addition of sulpiride completely abolished this effect (Supplemental Figure S4A -B). We next tested whether co-administration of both L-741,626 and PG01037 would recapitulate the effects of sulpiride. DA alone produced the expected reduction in spike frequency, and simultaneous co-administration of 1 nM L-741,626 + 1 nM PG01037 attenuated this effect (Supplemental Figure S4C -D). These findings suggest that DA-mediated inhibition of D2-MSN activity involves DA binding at both D2Rs and D3Rs, and that simultaneous blockade of both receptor subtypes may be necessary to temper the impact of DA on the D2-MSN's firing properties.
The Enhancement of Cocaine's Locomotor Stimulant Effects by D3R Antagonism Requires Intact D1R Signaling.
Based on the results of our FSCV and electrophysiological experiments, we hypothesized that D3R antagonism potentiates cocaine-induced locomotion in mice via a combination of two distinct neuropharmacological mechanisms in the NAc. First, D3R antagonism enhances cocaine-induced increases in DA release, likely via blockade of presynaptic D3Rs on DA terminals. Second, D3R antagonism results in potentiated excitation of D1-MSNs by DA, likely via blockade of postsynaptic D3Rs that normally provide inhibitory tone on these cells. These combined effects of D3R blockade create a scenario in which cocaine increases DA levels beyond its normal capacity, and this DA in turn hyperexcites D1-MSNs, thereby producing greater levels of locomotion as compared to cocaine alone. An important facet of this system is that although D1R signaling and D3R signaling oppose each other in D1-MSNs, the presence of some basal level of D1R-mediated excitation within these cells is ultimately required for the behavioral effects of cocaine to emerge. We therefore reasoned that a low level of D1R blockade should reduce cocaine-induced locomotion, and that this effect could be reversed with combined treatment of a D3R antagonist. However, if the level of D1R blockade was substantially strengthened, the effects of a D3R antagonist should be rendered ineffective because its capacity to enhance cocaine's behavioral effects is dependent upon some threshold amount of intact D1R signaling. To test these hypotheses, we performed a final set of locomotor activity studies in mice. Pretreatment with a low dose (0.03 mg/kg) of the D1like receptor antagonist SCH23390 caused a modest ~45% attenuation of the locomotoractivating effects of 3.0 mg/kg cocaine, and this effect was reversed by co-administration of 10.0 mg/kg PG01037 ( Figure 6A ; time course, Supplemental Figure S5A ). Increasing the dose of SCH23390 10-fold caused a greater (~63%) reduction in cocaine-induced locomotion, but coadministration of 10.0 mg/kg PG01037 had no impact on the effects of this higher dose of SCH23390 ( Figure 6B ; time course, Supplemental Figure S5B ). Collectively, these findings support the notion that D3R antagonism potentiates the stimulant effects of cocaine via a D1-like receptor-dependent mechanism.
Discussion
In the present study, we demonstrate that selective D3R antagonism enhances several facets of NAc DA neurotransmission and potentiates the behavioral-stimulant effects of cocaine, while selective D2R antagonism produces the opposite behavioral valence and attenuates cocaine's psychostimulant effect. Furthermore, we identify hyperexcitation of D1-MSNs as a likely mechanism by which D3R blockade uniquely facilitates NAc DA neurotransmission and associated behavior.
While nonselective antagonism of D2-like receptors has previously been reported to attenuate the locomotor-activating effects of cocaine (68, 69, 72) , the specific contributions of the D2-like receptor subtypes in mediating these effects have remained unclear. Results from our behavioral studies show that systemic pretreatment with the selective D2R antagonist L-741,626 attenuates the acute locomotor-stimulant effects of cocaine and abolishes the development of locomotor sensitization, while administration of the selective D3R antagonist PG01037 enhances cocaine's acute locomotor-stimulant effects and renders a low, ineffective dose of cocaine capable of inducing behavioral sensitization. Intra-NAc infusion of PG01037 recapitulated the effects of systemic administration, thus confirming the NAc as a key neuroanatomical substrate for modulation of cocaine-induced locomotion by D3R antagonism. The effects of D3R blockade are therefore in direct opposition to those reported previously for nonselective D2-like receptor antagonism (68, 69, 72) and for selective D2R antagonism in the present study, suggesting that the effect of nonselective D2-like receptor blockade on cocaineinduced locomotion is mediated predominantly by antagonism of the D2R in the NAc. This is supported by evidence that genetic deletion of the D2R subtype within striatal MSNs in mice diminishes the locomotor response to cocaine (73) . Moreover, our present results with PG01037 are in agreement with the previous finding that administration of another highly-selective D3R antagonist, NGB 2904, potentiates amphetamine-induced locomotor activity in mice (51) , as well as the reported hypersensitivity of various lines of D3R knockout mice to the behavioralstimulant effects of cocaine (52, 74) and amphetamine (50, 52) . Some studies have failed to detect enhanced stimulant-induced locomotor activity following D3R antagonism in rodents, but this discrepancy could be attributed to several factors including the use of compounds with low selectivity for D3R vs. D2R, use of a limited dose range of psychostimulants, etc. Our withinsubjects, multi-dose approach represents a significant advancement over previous investigations and reveals for the first time a clear leftward/upward shift of the cocaine doseresponse function, interpreted unequivocally as a pharmacological potentiation. Our observed enhancement of acute and repeated cocaine-induced locomotion following PG01037 administration can be attributed to changes in NAc DA neurotransmission exclusively for several reasons. First, psychostimulant-induced increases in rodent locomotion are strongly linked to the modulation of DA levels specifically within the NAc (75) (76) (77) . Second, the D3R is enriched in the mouse NAc as compared to other regions (23) (24) (25) . Finally, we show in the present study that intra-NAc infusion of PG01037 is sufficient to produce the enhanced behavioral response to cocaine.
D2Rs and D3Rs within the NAc are expressed both presynaptically on DAergic terminals and postsynaptically on MSNs (8, 9) . Because blockade of presynaptic DA autoreceptors typically results in enhanced presynaptic DA release (78) (79) (80) (81) , it seemed plausible that D3R antagonism may potentiate cocaine-induced locomotion, at least in part, by exacerbating cocaine-induced increases in extracellular DA. In support of this hypothesis, we found that application of PG01037 enhanced cocaine-induced increases in DA release and also significantly facilitated cocaine's inhibitory action on DA clearance. The effects we observed with PG01037 in our FSCV experiments are similar to those produced by another highly-selective D3R antagonist, SB-277011-A, (41, 44) , and mirror the facilitation of stimulant-induced increases in extracellular DA following systemic D3R antagonism (43) . Together, these studies and our present results indicate that presynaptic D3R antagonism potentiates stimulant-induced increases in NAc DA levels, even in the absence of any effects on basal DA concentrations. The exact mechanisms by which D3R antagonists exert these effects on DA release and clearance and why they only do so under conditions of increased DA levels remain to be determined, but possible explanations include disinhibition of the presynaptic terminal via autoreceptor blockade (8, 26, 27) and/or modulation of the structure and/or function of the dopamine transporter itself (41, 82) . Regardless, these actions are unlikely to wholly explain the facilitatory effects of D3R antagonism on cocaine-induced locomotion because application of L-741,626 to NAc slices produced effects similar to, and not opposite from, those produced by PG01037. The opposing influences of selective D2R and D3R antagonism on behavioral output related to NAc DA signaling do not therefore appear to be mediated by disparate effects on presynaptic DA release.
To the best of our knowledge, the present study represents the first assessment of selective D2R or D3R antagonism on DA-induced changes in D1-MSN and D2-MSN activity within the NAc. With respect to D2-MSNs, although neither L-741,626 nor PG01037 application alone blocked DA-mediated inhibition of D2-MSN activity, we found that their combined administration produced a partial blockade of DA's effects that resembled the effects of the nonselective D2/D3 receptor antagonist sulpiride, suggesting that simultaneous D2R and D3R antagonism may be required to fully prevent the inhibitory actions of DA on these cells. The finding that ineffective doses, when combined, produced a measurable change suggests that these compounds exert qualitatively similar rather than dissimilar effects on D2-MSN activity and that their combined effects are at least additive, if not synergistic, in nature in these cells. In contrast to their effects on D2-MSNs, we observed qualitative differences between selective D2R and D3R antagonism on DA-mediated excitation of D1-MSNs. The finding that L-741,626 failed to significantly alter the excitatory impact of DA on D1-MSNs was not surprising given the rarity of D2R co-expression in these cells (83) . However, a significant proportion of D1-MSNs in the NAc co-express the D3R (30, (33) (34) (35) , and accordingly we found that blockade of D3Rs via application of PG01037 modulated the activity of D1-MSNs, rendering them hyperexcitable to DA application. D1-like receptors are positively coupled to adenylyl cyclase via Gas protein activation and typically produce intracellular effects that promote neuronal excitation, while the D3R is negatively coupled to adenylyl cyclase via Gai/o protein activation and causes neuronal inhibition (8, 9) . When co-expressed in the same cells, these receptors may exert opposing influences on neuronal activity (84) . Therefore, the hypersensitivity to DA-mediated excitation exhibited by D1-MSNs in the presence of PG01037 likely reflects the removal of tonic inhibitory tone that would otherwise be provided by DA's activation of the D3R. As D1-like receptor activation has been positively linked with stimulant-induced locomotor output (85) (86) (87) (88) , our findings provide a plausible mechanistic explanation as to how D3R antagonism results in exacerbated stimulant-induced locomotion, i.e. through increased activation of NAc D1-MSNs via reductions in D3R-mediated inhibition. Consistent with this model, we found that D3R antagonism functionally opposed the reductions in cocaine-induced locomotion exerted by a low dose of the D1-like receptor antagonist SCH23390, likely because some residual level of D1-like receptor signaling remained that was sufficient to engender increased locomotor output when tonic D3R-mediated inhibition was antagonized. However, when the dose of SCH23390 was increased ten-fold, the D3R antagonist was rendered ineffective, probably because the level of D1-like receptor signaling was no longer sufficient to increase locomotor output. Our electrophysiological and behavioral studies are uniformly consistent with the hypothesis that D3R antagonism renders NAc D1-MSNs hyperresponsive to DA-induced excitation, and also provide mechanistic evidence as to how D3R antagonism functionally enhances the behavioral, cellular, and neurochemical effects of cocaine observed herein and previously by others (38, 41, 44, 74, 89, 90) .
In summary, we report that pretreatment with the selective D3R antagonist PG01037 enhances, while the selective D2R antagonist L-741,626 attenuates, the behavioral-stimulant effects of cocaine in mice. We also demonstrate that the effects of PG01037 are likely mediated by a two-pronged neuropharmacological modulation of NAc DA neurotransmission. First, D3R antagonism potentiates cocaine-induced increases in presynaptic DA release, and second, it causes hypersensitivity of NAc D1-MSNs to the excitatory effects of DA while lacking appreciable effects on D2-MSNs. Our results help to resolve a complicated and mixed literature regarding the impact of D3R antagonism on NAc-related signaling and behavioral output that will be of importance to those exploring D3R antagonists as potential pharmacotherapeutics for various DA-related disorders. 
Figure Legends
